Oppenheimer lowered the firm’s price target on Zimmer Biomet to $135 from $145 and keeps an Outperform rating on the shares. The firm is updating its estimates to reflect the ERP issues that arose in ...
Source LinkOppenheimer lowered the firm’s price target on Zimmer Biomet to $135 from $145 and keeps an Outperform rating on the shares. The firm is updating its estimates to reflect the ERP issues that arose in ...
Source Link
Comments